The utility of computed tomography in radiation therapy: an estimate of outcome

Quality, technology and outcomes: evolution and evaluation of new treatments and/or new technology

The pace of technological innovation and adoption continues to increase each year, and the field of Radiation Oncology struggles to react appropriately to the changes and potential improvements in treatment which hopefully will result from this innovation. The standard methods used in the past to test new technology and treatment techniques are often no longer appropriate for this fast-changing environment. This paper uses examples from radiotherapy technological developments over the last decades to illustrate issues which need to be solved in order to study and evaluate potential advances, and then describes several improved ways to study new techniques and technology. Design of appropriate studies can help us improve patient care while at the same time documenting which new clinical strategies, enabled by new technology, lead to improved patient outcomes.

An implantable radiation dosimeter for use in external beam radiation therapy

An implantable radiation dosimeter for use with external beam therapy has been developed and tested both in vitro and in canines. The device uses a MOSFET dosimeter and is polled telemetrically every day during the course of therapy. The device is designed for permanent implantation and also acts as a radiographic fiducial marker. Ten dogs (companion animals) that presented with spontaneous, malignant tumors were enrolled in the study and received an implant in the tumor CTV. Three dogs received an additional implant in collateral normal tissue. Radiation therapy plans were created for the animals and they were treated with roughly 300 cGy daily fractions until completion of the prescribed cumulative dose. The primary endpoints of the study were to record any adverse events due to sensor placement and to monitor any movement away from the point of placement. No adverse events were recorded. Unacceptable device migration was experienced in two subjects and a retention mechanism was developed to prevent movement in the future. Daily dose readings were successfully acquired in all subjects. A rigorous in vitro calibration methodology has been developed to ensure that the implanted devices maintain an accuracy of +/-3.5% relative to an ionization chamber standard. The authors believe that an implantable radiation dosimeter is a practical and powerful tool that fosters individualized patient QA on a daily basis.

Use of three-dimensional spiral computed tomography imaging for staging and surgical planning of head and neck cancer

We compare four different three-dimensional (3D) reconstruction methods of spiral computed tomography (CT) data for head and neck cancer to establish the method best suited for specific uses, eg, staging of lymph nodes and viewing of spatial relationships between the tumor, fascial spaces, adjacent soft tissues, and others structures. We evaluated a series of 10 patients (six men and four women), aged 32 to 60 years. Of these, five were histologically diagnosed with squamous cell carcinoma, two with lymphoma, one with thyroid cancer, one with Kikuchi's disease or necrotizing lymphadenitis, and one with esthesioneuroblastoma. All scans were obtained using high-resolution spiral CT (General Electric Medical Systems, Milwaukee, WI). The collimations used were 3 mm and 5 mm, matrix 512 x 512, and reconstruction interval not more than 3 mm. Scanning was performed from the skull base to the aortic arch. Iodinated contrast medium was injected so that the blood vessels were clearly differentiated from nodes. Different techniques of three-dimensional reconstruction were employed, including shaded surface display (SSD), multiplanar reconstructions (MPR), maximum intensity projection (MIP), 3D volume rendering (VR), and combined techniques. The reconstructions were performed in a variety of planes, including sagittal, coronal, and oblique views. In our series of selected patients, the technique of 3D VR showed potential advantages over other techniques. The MIP technique was useful in analyzing the patency of vessels and to exclude thrombus, compression, or displacement by tumor. The use of combined techniques such as SSD and MPR, accurately demonstrated the levels of lymph nodes and the relationship between the tumor projection of interest and various anatomic structures. In conclusion, 3D reconstruction of CT data is useful in the localization and staging of neck tumors and assists in surgical planning and radiation treatment.

Volumetric visualization of head and neck CT data for treatment planning

PURPOSE

To demonstrate the utility of volume rendering, an alternative visualization technique to surface rendering, in the practice of CT based radiotherapy planning for the head and neck.

METHODS AND MATERIALS

Rendo-avs, a volume visualization tool developed at the University of Chicago, was used to volume render head and neck CT scans from two cases. Rendo-avs is a volume rendering tool operating within the graphical user interface environment of AVS (Application Visualization System). Users adjust the opacity of various tissues by defining the opacity transfer function (OTF), a function which preclassifies voxels by opacity prior to rendering. By defining the opacity map (OTF), the user selectively enhances and suppresses structures of various intensity. Additional graphics tools are available within the AVS network, allowing for the manipulation of perspective, field of view, data orientation. Users may draw directly on volume rendered images, create a partial surface, and thereby correlate objects in the 3D scene to points on original axial slices. Information in volume rendered images is mapped into the original CT slices via a Z buffer, which contains the depth information (Z coordinate) for each pixel in the rendered view. Locally developed software was used to project conventionally designed GTV contours onto volume rendered images.

RESULTS

The lymph nodes, salivary glands, vessels, and airway are visualized in detail without prior manual segmentation. Volume rendering can be used to explore the finer anatomic structures that appear on consecutive axial slices as "points." Rendo-avs allowed for acceptable interactivity, with a processing time of approximately 5 seconds per 256 x 256 pixel output image.

CONCLUSIONS

Volume rendering is a useful alternative to surface rendering, offering high-quality visualization, 3D anatomic delineation, and time savings to the user, due to the elimination of manual segmentation as a preprocessing step. Volume rendered images can be merged with conventional treatment planning images to add anatomic information to the treatment planning process.

The delta-TCP concept: a clinically useful measure of tumor control probability

PURPOSE

The aim of this article is to provide a quantitative tool to evaluate the influence of the different dose regions in a non-uniformly irradiated tumour upon the probability of controlling that tumor.

METHODS AND MATERIALS

First, a method to generate a distribution of the probability of controlling the cells in a voxel (VCP) is explored and found not to be useful. Second, we introduce the concept of delta-TCP, which represents the gain or loss in the overall TCP as a result of each particular bin in a DVH not receiving the prescribed dose (the same concept is applicable to dose cubes or to a fraction of the bin). The delta-TCP method presented here is based on the Poisson TCP model, but any other model could also be used. Third, using this tool, with parameters appropriate to Stage C prostate tumors, the consequences of "cold" and "hot" dose regions have been explored.

RESULTS

We show that TCP is affected by the minimum dose, even if it is delivered to a very small volume (20% dose deficit to 5% of the volume makes the TCP decrease by 18%), and that a hot region may be "wasted" unless the boost is to the bulk of the volume. An example of the application of the delta-TCP concept to a prostate radiotherapy plan is also given.

CONCLUSION

The delta-TCP distribution adds more objective information to the original DVH by enabling the clinician or planner to directly evaluate the effects of a non-uniform dose distribution on local control.

Characteristics and clinical application of a treatment simulator with Ct-option

BACKGROUND AND PURPOSE

The integration of a scanner for computed tomography (CT) and a treatment simulator (Sim-CT, Elekta Oncology Systems, Crawley, UK) has been studied in a clinical situation. Image quality, hounsfield units (HU) and linearity have been evaluated as well as the implications for treatment planning. The additional dose to the patient has also been highlighted.

MATERIAL AND METHODS

Image data is acquired using an array of solid state X-ray detectors attached externally to the simulator's image intensifier. Three different fields of view (FOV: 25.0 cm, 35.0 cm and 50.0 cm) with 0.2 cm, 0.5 cm and 1.0 cm slice thickness can be selected and the system allows for an aperture diameter of 92.0 cm at standard isocentric height. The CT performance has been characterized with several criteria: spatial resolution, contrast sensitivity, geometric accuracy, reliability of hounsfield units and the radiation output level. The spatial resolution gauge of the nuclear associates quality phantom (NAQP) as well as modulation transfer functions (MTF) have been applied to evaluate the spatial resolution. Contrast sensitivity and HU measurements have been performed by means of the NAQP and a HU conversion phantom that allows inserts with different electron densities. The computed tomography dose index (CTDI) of the CT-option has been monitored with a pencil shaped ionization chamber. Treatment planning and dose calculations for heterogeneity correction based on the Sim-CT images generated from an anthropomorphic phantom as well as from ten patients have been compared with similar treatment plans based on identical, yet diagnostic CT (DCT) images.

RESULTS

The last row of holes that are resolved in the spatial resolution gauge of the NAQP are either 0.150 cm or 0.175 cm depending on the FOV and the applied reconstruction filter. These are consistent with the MTF curves showing cut-off frequencies ranging from 5.3 lp/cm to 7.1 lp/cm. Linear regression analysis of HU versus electron densities revealed a correlation coefficient of 0.99. Contrast, pixel size and geometric accuracy are within specifications. Computed tomography dose index values of 0.204 Gy/As and 0.069 Gy/As have been observed with dose measurements in the center of a 16 cm diameter and 32 cm diameter phantom, respectively for large FOV. Small FOV yields CTDI values of 0.925 Gy/As and 0.358 Gy/As which is a factor ten higher than the results obtained from a DCT under similar acquisition conditions. The phantom studies showed excellent agreement between dose distributions generated with the Sim-CT and DCT HU. The deviations between the calculated settings of monitor units as well as the maximum dose in three dimensions were less than 1% for the treatment plans based on either of these HU both for pelvic as well as thoracic simulations. The patient studies confirmed these results.

CONCLUSIONS

The CT-option can be considered as an added value to the simulation process and the images acquired on the Sim-CT system are adequate for dose calculation with tissue heterogeneity correction. The good image quality, however, is compromised by the relative high dose values to the patient. The considerable load to the conventional X-ray tube currently limits the Sim-CT to seven image acquisitions per patient and therefore the system is limited in its capability to perform full three-dimensional reconstruction.

In vivo dosimetry during external photon beam radiotherapy

In this critical review of the current practice of patient dose verification, we first demonstrate that a high accuracy (about 1-2%, 1 SD) can be obtained. Accurate in vivo dosimetry is possible if diodes and thermoluminescence dosimeters (TLDs), the main detector types in use for in vivo dosimetry, are carefully calibrated and the factors influencing their sensitivity are taken into account. Various methods and philosophies for applying patient dose verification are then evaluated: the measurement of each field for each fraction of each patient, a limited number of checks for all patients, or measurements of specific patient groups, for example, during total body irradiation (TBI) or conformal radiotherapy. The experience of a number of centers is then presented, providing information on the various types of errors detected by in vivo dosimetry, including their frequency and magnitude. From the results of recent studies it can be concluded that in centers having modern equipment with verification systems as well as comprehensive quality assurance (QA) programs, a systematic error larger than 5% in dose delivery is still present for 0.5-1% of the patient treatments. In other studies, a frequency of 3-10% of errors was observed for specific patient groups or when no verification system was present at the accelerator. These results were balanced against the additional manpower and other resources required for such a QA program. It could be concluded that patient dose verification should be an essential part of a QA program in a radiotherapy department, and plays a complementary role to treatment-sheet double checking. As the radiotherapy community makes the transition from the conventional two-dimensional (2D) to three-dimensional (3D) conformal and intensity modulated dose delivery, it is recommended that new treatment techniques be checked systematically for a few patients, and to perform in vivo dosimetry a few times for each patient for situations where errors in dose delivery should be minimized.

High-dose conformal radiotherapy influenced the pattern of failure but did not improve survival in glioblastoma multiforme

BACKGROUND AND PURPOSE

Although glioblastoma multiforme is clearly radiation-resistant, there is evidence of a dose-dependent response relationship. The purpose of the study was to evaluate the impact of higher dose by rotational multileaf collimator (MLC) conformal radiation therapy.

MATERIALS AND METHODS

From 1984 to 1995, 38 consecutive cases with intracranial glioblastoma multiforme were treated using the rotational MLC conformal therapy. There were 25 men and 13 women with a median age of 47 years (12-73 years, mean 46.5 years). Median Karnofsky performance score was 80 (30-100, mean 78.2). Median tumor volume was 64 cc (8-800 cc, mean 110.3 cc). All underwent surgical intervention (only biopsy in 1, partial resection in 13, subtotal resection in 21, and gross total resection in 3). Radiation dose to was 60 to 80 Gy (median 68.5 Gy, mean 68.3 Gy) in 21 patients treated before 1990 and 90 Gy in the 17 patients thereafter. Biweekly i.v. chemotherapy was also administered for both arms.

RESULTS

The 1-year, 2-year, 5-year, and 10-year overall survival rates were 75%, 42%, 20%, and 15%, respectively. Univariate analysis showed the initial tumor volume, residual tumor volume, and Karnofsky performance score were statistically significant factors for survival. Only the residual tumor volume was statistically significant by multivariate analysis. The 5-year survival rate of patients with residual tumors of 5 cc or less in volume was as good as 37%. Survival of the 90-Gy Group appeared inferior to that of the Low-Dose Group, though no statistical difference was seen (the 3-year survival was 40% vs. 22%). Local failure was observed in 16 of the 19 recurrences in the Low-Dose Group, whereas it was observed in only 4 of the 13 recurrences in the 90-Gy Group. The difference in pattern of failure was statistically significant. Two patients of the High-Dose Group developed radiation necrosis and one died of it.

CONCLUSIONS

The high-dose conformal radiotherapy did not improve survival in the disease, but did change the pattern of failure.

CT virtual simulation

Advances in computer technology and software design have enabled the concept of virtual simulation, first suggested by George Sherouse, to be realized. This article reviews the hardware and software requirements that provide a system that feels like a simulator and can facilitate the 3D planning process. Fast digital reconstruction of a radiograph from a CT data set provides true verification of treatment field design within the constraints of the virtual method. The clinical application of this technique is discussed in detail in relation to particular treatment sites.

Quantifying the position and steepness of radiation dose-response curves

Radiation dose-response curves are of fundamental importance both in practical radiotherapy and as the basis of more theoretical considerations concerning the potential benefit to be gained from modified dose-fractionation schedules or of the effects of dosimetric and biological variability. The steepness of the dose-response curve is a key parameter and quantitative measures of steepness derived from clinical data are strongly needed. Unfortunately, there are many ambiguities associated with quantifying the steepness of radiation dose-response curves and these are identified and discussed in the present paper. The following problems are reviewed. (1) In the literature, various descriptors of 'steepness' are reported. We focus on the normalized dose-response gradient, gamma, and the dose-response slope, theta. The mathematical properties and the relationship between these are discussed. (2) Steepness estimates depend on the mathematical model used to describe the dose response relationship. Three standard formulations are considered: the Poisson, the logistic and the probit dose-response model. The magnitude of the model dependence is influenced by the range of the empirical dose-response data available, and is most pronounced for data concentrated around very low or very high response levels. (3) Reparametrizations of the standard models in terms of position and steepness are given, and it is pointed out that some previously published formulas are only approximations. (4) The method of analysis can influence the steepness estimate. An analysis of a specific data set shows that the use of the least-squares method rather than the preferred maximum likelihood method may influence both the steepness estimate and its confidence interval. (5) Dose-response data generated with a fixed number of fractions rather than a fixed dose per fraction will produce steeper dose-response curves. The approximation involved in describing such a set of dose-response data by a position and a single steepness parameter is discussed. (6) The importance of specifying the statistical uncertainty of the steepness estimate is stressed. All of these problems are illustrated by a practical example, in which dose-response data from the literature are re-analysed.

Combined proton and photon conformal radiation therapy for locally advanced carcinoma of the prostate: preliminary results of a phase I/II study

PURPOSE

A study was developed to evaluate the use of combined photons and protons for the treatment of locally advanced carcinoma of the prostate. This report is a preliminary assessment of treatment-related morbidity and tumor response.

METHODS AND MATERIALS

One hundred and six patients in stages T2b (B2), T2c (B2), and T3 (C) were treated with 45 Gy photon-beam irradiation to the pelvis and an additional 30 Cobalt Gray Equivalent (CGE) to the prostate with 250-MeV protons, yielding a total prostate dose of 75 CGE in 40 fractions. Median follow-up time was 20.2 months (range: 10-30 months). Toxicity was scored according to the Radiation Therapy Oncology Group (RTOG) grading system; local control was evaluated by serial digital rectal examination (DRE) and prostate specific antigen (PSA) measurements.

RESULTS

Morbidity evaluation was available on 104 patients. The actuarial 2-year rate of Grade 1 or 2 late morbidity was 12% (8% rectal, 4% urinary). No patients demonstrated Grade 3 or 4 late morbidity. Treatment response was evaluated on 100 patients with elevated pretreatment serum PSA levels. The actuarial 2-year rate of PSA normalization was 96%, 97%, and 63% for pretreatment PSAs of > 4-10, > 10-20, and > 20, respectively. The 13 patients with rising PSA demonstrated local recurrence (3 patients), distant metastasis (8 patients), or no evidence of disease except increasing PSA (2 patients).

CONCLUSIONS

The low incidence of side effects, despite the tumor dose of 75 CGE, demonstrates that conformal protons can deliver higher doses of radiation to target tissues without increasing complications to surrounding normal tissues. The initial tumor response, as assessed by the high actuarial rate of normalization with pretreatment PSA < or = 20, and the low rate of recurrences within the treatment field (2.8%), are encouraging.

Adaptive radiation therapy

Adaptive radiation therapy is a closed-loop radiation treatment process where the treatment plan can be modified using a systematic feedback of measurements. Adaptive radiation therapy intends to improve radiation treatment by systematically monitoring treatment variations and incorporating them to re-optimize the treatment plan early on during the course of treatment. In this process, field margin and treatment dose can be routinely customized to each individual patient to achieve a safe dose escalation.

Tumor volume and local control probability: clinical data and radiobiological interpretations

PURPOSE

It is well established for certain human tumor histologies that increasing tumor volume leads to a decreasing probability of tumor control. The simplest explanation for these findings is that the number of tumor clonogens that must be sterilized to control a tumor increases with tumor volume. In this investigation we consider whether clinical evidence favors a further hypothesis, namely, that clonogen number increases in direct proportion to tumor volume.

METHODS AND MATERIALS

Previously published data on the volume-cure relationship for breast tumors, neck nodes, malignant melanoma, and squamous cell carcinomas of the oropharynx and the uterine cervix were analyzed.

RESULTS

We found in all these data sets evidence that the effect of tumor volume on tumor control probability was less than what would be expected under the assumption of proportionality between number of clonogens and volume. We describe good reasons to believe that this is the result of patient-to-patient variability in radiocurability, and possibly other factors as well.

CONCLUSIONS

Clinical data do provide evidence for a highly significant reduction of tumor control probability with increasing tumor volume. However, because of heterogeneity in patient and tumor characteristics, the volume effect is less pronounced than would be expected from a simple proportionality between number of clonogens and volume. In principle this simple proportionality does hold in individual patients, so that standard approaches for treatment plan optimization in individuals may still be valid.

Picture archiving and communications systems in radiation oncology (PACSRO): tools for a physician-based digital image review system

Digital imaging is becoming more and more important in the diagnosis, staging, and treatment of patients in radiation oncology. In order to facilitate the most efficient interface of this technology to physicians and other users of this information, a medical image display system (MID) has been developed at the Fox Chase Cancer Center (FCCC). The system runs on 20 personal computers situated in physicians offices as well as a modified system located in the radiation oncology conference room. Access to CT, MRI, and EPID information is achieved through an Ethernet connection to the hospital picture archiving and communications system (PACS). Over a 1-year period a total of 503 patients and 3845 images have been stored on the system. Physician approval using the MID system (without conventional films) was performed on 106 patients. Of these, 22%, 16%, 11%, 10%, and 9% consisted of breast, prostate, pelvic, lung, and head and neck patients, respectively. Digital images sent from a variety of image sources to the MID system take up to 15 s to process and format while image access and display can take 2-5 s, dependent upon image size and speed of the host computer.

Integrated software tools for the evaluation of radiotherapy treatment plans

PURPOSE

This article announces the availability of a convenient and useful software environment for the evaluation of three-dimensional (3D) radiotherapy treatment plans.

MATERIALS AND METHODS

Using standards such as American National Standards for Information Systems C and the X Window System allowed us to bring the computation and display of dose-volume histograms, dose statistics, tumor control probabilities, normal tissue complication probabilities, and a figure of merit together under one user interface. These plan evaluation tools are not stand alone, but must interact with a 3D radiation therapy planning system to obtain the required dose matrices and patient anatomical contours. Installation of the software involves a programmer who writes a software bridge between the radiation therapy planning system and the tools, thereby providing access to local data files. This design strategy confines portability issues to one area of the software.

RESULTS

Access to the other tools is through the Graphical Plan Evaluation Tool (GPET). GPET coordinates the use of each of the tools and provides graphical facilities for display of their results. Importantly, GPET assures that the displayed results of each tool have been computed with the same input specifications for all treatment plans being compared. For added convenience, the user can rearrange the resultant data to be reviewed in various ways on the video screen. The software design also allows incorporation of customized algorithms and input data for computing tumor control probability and normal tissue complication probabilities, since those currently available are controversial.

CONCLUSION

The Graphical Plan Evaluation Tool unifies the simultaneous computation for several analytical tools and graphical display of their results. Within the constraints of the X Window System environment, this assemblage of software tools provides a portable, flexible, and convenient method for the quantitative evaluation of several radiotherapy treatment plans.

Design of a fully integrated three-dimensional computed tomography simulator and preliminary clinical evaluation

PURPOSE

We describe the conceptual structure and process of a fully integrated three-dimensional (3-D) computed tomography (CT) simulator and present a preliminary clinical and financial evaluation of our current system.

METHODS AND MATERIALS

This is a preliminary report on 117 patients treated with external beam radiation therapy alone on whom a 3-D simulation and treatment plan and delivery were carried out from July 1, 1992, through June 30, 1993. The elements of a fully integrated 3-D CT simulator were identified: (a) volumetric definition of tumor volume and patient anatomy obtained with a CT scanner, (b) virtual simulation for beam setup and digitally reconstructed radiographs, (c) 3-D treatment planning for volumetric dose computation and plan evaluation, (d) patient-marking device to outline portal on patient's skin, and (e) verification (physical) simulation to verify portal placement on the patient. Actual time-motion (time and effort) recording was made by each professional involved in the various steps of the 3-D simulation and treatment planning on computer-compatible forms. Data were correlated with the anatomic site of the primary tumor being planned. Cost accounting of revenues and operation of the CT simulator and the 3-D planning was carried out, and projected costs per examination, depending on case load, were generated.

RESULTS

Average time for CT volumetric simulation was 74 min without or 84 min with contrast material. Average times were 36 min for contouring of tumor/target volume and 44 min for normal anatomy, 78 min for treatment planning, 53 min for plan evaluation/optimization, and 58 min for verification simulation. There were significant variations in time and effort according to the specific anatomic location of the tumor. Portal marking of patient on the CT simulator was not consistently satisfactory, and this procedure was usually carried out on the physical simulator. Based on actual budgetary information, the cost of a volumetric CT simulation (separate from the 3-D treatment planning) showed that 1500 examinations per year (six per day in 250 working days) must be performed to make the operation of the device cost effective. The same financial projections for the entire 3-D planning process and verification yielded five plans per day. Some features were identified that will improve the use of the 3-D simulator, and solutions are offered to incorporate them in existing devices.

CONCLUSIONS

Commercially available CT simulators lack some elements that we believe are critical in a fully integrated 3-D CT simulator. Sophisticated 3-D simulation and treatment planning can be carried out in a significant number of patients at a reasonable cost. Time and effort and therefore cost vary according to the anatomic site of the tumor being planned and the number of procedures performed. Further efforts are necessary, with collaboration of radiation oncologists, physicists, and manufacturers, to develop more versatile and efficient 3-D CT simulators, and additional clinical experience is required to make this technology cost effective in standard radiation therapy of patients with cancer.

Assurance of high quality linac-based stereotactic radiosurgery

PURPOSE

Stereotactic radiosurgery is generally a single, high-dose radiation treatment for the brain requiring targeting accuracy on the order of a millimeter. From the initial implementation of radiosurgery, therefore, quality assurance is an ongoing process of paramount importance. In this paper, we outline the basic elements of a quality assurance program for our linear accelerator that has been in use at Washington University Medical Center over the past 2 years.

METHODS AND MATERIALS

Various devices and procedures have been developed to verify the accuracy and safety of the stereotactic radiosurgery regimen. Specifically, we present methods for assessing the attainment of spatially correct patient images, the reliability of the computerized treatment planning system, achieving physical safety for the patient, as well as the proper operation of the radiation treatment device.

RESULTS

Our procedures have allowed us to assure quality patient treatments and, additionally, has permitted monitoring our performance for continual improvement. For example, a plot of targeting accuracy with the number of patients shows an asymptotic approach to a value within 0.6 mm of that ideally expected.

CONCLUSION

To maintain high-quality patient care, one must review critical aspects of the treatment regimen on a periodic basis. Providing for the appropriate level of staff training, periodic reviews of procedures and maintenance of forms are also very important.

Study on the reference dose level in radiotherapy treatment planning

PURPOSE

The reference dose level of the dose distribution in the tumor volume is studied.

METHODS AND MATERIALS

The study is performed using a formula based on the Linear Quadratic (LQ) model. The calculated reference dose level to which the prescribed dose must be referred, for the eradication of a homogeneous tumor, is investigated by varying the dose distribution, that is, the dose volume histogram shape, its range, the prescribed total dose, the fraction size and the linear quadratic model parameters, alpha and beta.

RESULTS

For all the simulated dose volume histograms the calculated reference dose level is lower than the mean dose level, depending on the range of dose variation and the considered tumor sensitivity. When the dose nonuniformity is not too great the reference dose level is very near to the mean dose level; when the inhomogeneity of dose distribution is high the reference level is clearly lower than the mean level but not necessarily equal to the minimum level in the tumor. For the dose volume histograms derived from the actual dose distributions obtained from a two tangential beams technique, a four beams technique and a moving beam technique, the reference levels are calculated and compared with the ICRU 29 reference point dose level. In two cases the reference levels are lower than the level at the ICRU 29 reference point. In the case of the four beams technique, the two levels are equal.

CONCLUSION

These theoretical results show the possibility of administering the prescribed dose to a dose level higher than the minimum in the tumor, with the same value of Tumor Control Probability (TCP) as the one corresponding to a uniform tumor irradiation. The application of the proposed study can offer a general support to the choice of the reference dose level, based on the actual dose distribution in the tumor volume.

Evaluation of tabletop materials for autocontouring in CT treatment planning

Computerized tomography (CT) treatment planning has been proven to be essential in precision radiotherapy. Typically CT planning requires a large number of CT scans (between 3 and 50 slices) to be entered into the treatment planning system. A significant amount of time in the planning process is devoted to outlining internal structures, organs, and the external patient contour in each CT slice. In principle, external contours could be generated easily using autocontouring routines; however, in reality it does not always provide a satisfactory contour due to the limitations of the CT tabletop having nearly the same CT number as that of the body structure. A solution to this problem is to create a large CT number gradient interface between the patient and CT tabletop by inserting a thin sheet of low CT number material. The optimum material for a tabletop was investigated from a range of low-density and low atomic number media. Various materials were studied by placing them underneath an unsliced humanoid phantom. A portion of the phantom abdomen was imaged and analyzed on a Picker Premier IQ CT scanner. Results indicate that the tabletop should be made of the material that has a CT number at least 10 times lower than the tissue in contact with the table. A simple and cost-effective method of avoiding failures in autocontouring is to place a thin sheet of low-density material such as cardboard or foam board on the tabletop. Such an insert creates a large CT gradient resulting in a significant improvement in the accuracy of the edge detection algorithm used for autocontouring. Detailed analysis is presented.

The value of routine computed tomography scanning of the chest in patients presenting with supradiaphragmatic Hodgkin's disease

Six patients presenting with supradiaphragmatic Hodgkin's disease are presented to demonstrate the potential benefits of chest computed tomography (CT) scanning as a routine staging procedure. These cases show that CT scanning can detect mediastinal and lung involvement not readily detected by other investigations, and that such findings can influence the radiotherapy plan, the need for extended radiotherapy fields or the use of chemotherapy. Following treatment, CT scanning can be useful to assess treatment response and may permit earlier detection of relapse. The use of chest CT scanning as a routine staging procedure in all patients with supradiaphragmatic Hodgkin's disease is advocated.

Quantification of doses to mediastinal lymph nodes in Hodgkin's disease

Hodgkin's disease is highly curable today. Radiotherapy (RT) is the treatment of choice in the early stages. A mantle field is often used in the RT of Hodgkin's disease, and the technique and dosimetry are quite complex. We used computerized tomography (CT)-based dosimetry to determine doses delivered to different mediastinal nodes with the commonly used technique in Hodgkin's disease that was originally described by Kaplan. We used dose-volume histograms to determine doses to various groups of nodes in nine patients. Significant inhomogeneity (30%, 30%, 35%, 35%, 30%, 40%, 35%, 35%, and 30% in the nine patients) in dose distribution was found within the mediastinum. With the advent of 3-dimensional CT-based treatment planning, we are able to quantify such inhomogeneities. The question arises whether a homogeneous, lesser dose can achieve equal results. Average doses and "effective doses" were also calculated. The "effective doses" in eight patients (for a prescribed dose of 44 Gy) with a midline posterior spinal cord block added at 20 Gy were 37.3 Gy, 34.3 Gy, 36.0 Gy, 38.4 Gy, 35.8 Gy, 38.1 Gy, 36.7 Gy, and 36.7 Gy, respectively. A homogeneous dose equivalent to effective dose may achieve the same control as an inhomogeneous dose delivery. Prospective 3-D dosimetric studies are required to confirm this concept.

Can modest escalations of dose be detected as increased tumor control?

Clinically defined groups of tumors are usually characterized by shallow dose-response curves, and this results from heterogeneity among individual dose-response curves, each of which is very likely quite steep. A review of published results for human tumors indicates that a 10% escalation of dose to tumors controlled at the 50% level, where changes in outcome are most likely to be detected, will be detectable in a population of unselected patients only in sizable clinical trials (130-300 patients per dose level). With a few exceptions, a dose escalation of 20% will be detectable in much smaller trials (50-130 patients per dose level). Therefore, clinical trials of improved treatment modalities will be confounded by patient heterogeneity, and modest improvements may go undetected in all but the largest trials. Mathematical modeling was used to study the effect on the steepness of the dose-response curve of selecting patients on the basis of the radiosensitivity measure SF2 (surviving fraction at 2 Gy). If SF2 is a faithful predictor of response in a group of tumors, then heterogeneity could be reduced by excluding the patients with the most sensitive (controlled with near certainty) and most resistant (recurring with near certainty) tumors. The resulting "stochastic fraction" (tumors for which treatment outcome is probabilistic) would be characterized by a steep dose response, and the number of patients required to demonstrate the effect of dose escalation would be substantially reduced (by about 50%).

Does improved depth dose characteristics and treatment planning correlate with a gain in therapeutic results? Evidence from past clinical experience using conventional radiation sources

Experience with the use of external beam conventional radiation over a period of several decades has shown that in every instance where there has been a major advance in the physical delivery of radiation to the tumor (beam energy and characteristics and precise tumor dose delivery) there has been a corresponding major improvement in the treatment results. The advent of megavoltage sources following the invention and use of Cobalt 60 and medical linear accelerator units during the late 1940's and early 1950's and their major impact on tumor control and patient survival in solid tumors such as carcinoma of the prostate, Hodgkin's Disease, head and neck tumors and cancer of the cervix are being discussed. Most recently, the use of computerized tomography and computer systems for treatment planning is likely to show a further improvement in the therapeutic results.

Beams eye view-based photon radiotherapy I

Geographic miss, dosimetric miss (underdosing), and proximity of the tumor to sensitive normal tissues are some of the causes of inadequate radiation dose delivery; this is one of many causes of failure after radiotherapy. In the past decade, computerized tomography (CT)-based treatment planning has helped to overcome some of these problems. Beam's eye view (BEV)-based radiotherapy planning is an improvement over CT-based treatment planning that may further increase the therapeutic ratio. Since January 1988, we have treated 198 patients with BEV-based photon radiotherapy. About 40% of our patients treated with radical radiotherapy undergo BEV-based treatment, and about 70% of patients who undergo planning CT in the treatment position receive BEV-based radiotherapy. Our findings are as follows: (a) routine use of BEV-based RT (BEVRT) is possible in a busy radiation oncology department; (b) BEVRT improves geometric coverage of tumors; (c) BEVRT is extremely useful in the design of oblique portals; (d) time commitments for various members of the RT treatment-planning team are reasonable; (e) BEVRT helps individualize RT technique; (f) preliminary data suggest decreased acute toxicity with the use of BEVRT for prostate cancer patients. Whether these advantages will help to improve the outcome (i.e., improve local control and survival) and/or decrease the long-term toxicity is not yet known.

The biological basis for conformal three-dimensional radiation therapy

The recent introduction of new computer technology for treatment planning and computer-driven treatment delivery systems, such as multi-leaf collimators and on-line verification systems, has accelerated the development of 3-dimensional (3-D) radiation therapy as a modality for curative cancer treatment. The goal of 3-D treatment planning is to conform the spatial distribution of the high radiation dose to the shape of the tumor contour while concomitantly decreasing the volume of the surrounding normal tissues receiving high radiation doses. The improved precision of tumor coverage and the exclusion of normal tissues should permit tumor dose escalation and may enhance local tumor control. It has been suggested that any survival gains derived from improvements in local control may be offset by the subsequent appearance of distant metastases arising from micrometastases already present at the time of initial diagnosis. However, clinical and laboratory studies indicate that failure to control the primary tumor at the time of initial treatment significantly increases the incidence of metastatic dissemination. This phenomenon is consistent with the hypothesis that the enhanced mitotic activity associated with the re-growth process of locally recurring primary tumors promotes the multi-step transformation of non-metastatic tumor cells into clonogens with metastatic potential, leading to increased overall rates of metastatic disease. These biologic considerations provide support for the need to focus attention on the identification of more effective therapeutic strategies designed to eradicate the primary local tumor completely at the time of initial therapy and serve as the rationale for clinical studies using 3-D conformal radiation therapy.

Virtual simulation: initial clinical results

We have developed a graphics-based three-dimensional treatment design system that permits the physician to easily understand which anatomy will be treated for any arbitrary beam orientation. Our implementation of this system differs from others in that the software (the Virtual Simulator) simulates the full functionality of a (physical) radiation therapy simulator allowing it to be easily used by physicians. The details of the of our initial clinical experience with virtual simulation are presented in this paper. Virtual simulation was attempted in 71 patients and completed in 65. In 41/71 patients (58%), the beam orientations chosen differed significantly from those traditionally used in our department. Although virtual simulation lead to traditional radiation portals in the remaining patients, in 23/71 (32%) secondary blocking was designed which was different from that which would have been conventionally employed. Thus, overall, virtual simulation lead to treatment changes in 64/71 (90%) of the patients in whom it was attempted. In 78% of evaluable patients the treatment designed with virtual simulation could be implemented on the physical simulator with a precision of +/- 5 mm (+/- 3 mm for brain and head and neck). Thus virtual simulation allowed both accurate planning and execution of treatment plans that would be difficult to achieve with conventional methods.

Recent advances in radiotherapy treatment planning

Radiation treatment planning is currently in a state of rapid change. Dissatisfaction with past planning technology stems from the growing realization that: (1) Increases in the local regional tumor control rate will increase the cure rate in many malignancies. (2) Even at the best treatment centers geometric tumor misses are commonplace. (3) Traditional constraints on treatment techniques, originally imposed for simplicity and reproducibility, are no longer necessary, and can result in suboptimal treatment. (4) Treatment plans judged "optimal" in two dimensions may be far from optimal when viewed over the entire treatment volume. (5) Lack of treatment reproducibility is also commonplace, and can be demonstrated to adversely affect treatment outcome. On the positive side, recent developments in computer graphics, image processing, radiation physics, and radiation biology are now making it possible to define, design, and deliver sophisticated 3D radiation treatments. However, because many of these technologies are being developed for other disciplines, their applicability to radiation therapy treatment planning is not widely appreciated. We outline the current status and new developments in radiation therapy treatment planning.

What degree of accuracy is required and can be achieved in photon and neutron therapy?

In this paper an attempt is made to formulate criteria for the accuracy in the delivery of absorbed dose to a patient during photon or neutron therapy. These requirements are mainly based on the relative steepness of dose-effect curves for local tumour control and normal tissue damage. A review of these dose-effect curves after photon irradiation shows a great variety in steepness; the curves for normal tissue complications in general may be steeper than those for local tumour control. From these data a standard requirement for the combined uncertainty of type A (random) and type B (systematic), given as one relative standard deviation, in the absorbed dose delivery of 3.5% is proposed, even though it is known that in many cases larger values are acceptable and in a few special cases an even smaller value should be aimed at. From the available radiobiological and clinical data it can be concluded that no statistically significant difference can be observed in the relative steepness of dose-effect curves after photon or neutron irradiation. Similar limits will thus be requested in neutron therapy. The uncertainties in the various steps involved in the delivery of an absorbed dose to a point in a patient have been analysed for a treatment with two parallel-opposed beams. The results of this analysis showed that even for these simple treatment conditions, the required accuracy in the delivery of the absorbed dose cannot completely be obtained in photon therapy, and not nearly in neutron therapy. The uncertainties in physical, radiobiological and clinical approaches for weighting of the biological effectiveness of neutron radiation have been compared. The uncertainty in the RBE ratio will replace the type B uncertainty in the absorbed dose during patient treatment if the same dosimetry protocol is applied during biological and clinical procedures.

Optimization of radiation therapy, III: A method of assessing complication probabilities from dose-volume histograms

To predict the likelihood of success of a therapeutic strategy, one must be able to assess the effects of the treatment upon both diseased and healthy tissues. This paper proposes a method for determining the probability that a healthy organ that receives a non-uniform distribution of X-irradiation, heat, chemotherapy, or other agent will escape complications. Starting with any given dose distribution, a dose-cumulative-volume histogram for the organ is generated. This is then reduced by an interpolation scheme (involving the volume-weighting of complication probabilities) to a slightly different histogram that corresponds to the same overall likelihood of complications, but which contains one less step. The procedure is repeated, one step at a time, until there remains a final, single-step histogram, for which the complication probability can be determined. The formalism makes use of a complication response function C(D, V) which, for the given treatment schedule, represents the probability of complications arising when the fraction V of the organ receives dose D and the rest of the organ gets none. Although the data required to generate this function are sparse at present, it should be possible to obtain the necessary information from in vivo and clinical studies. Volume effects are taken explicitly into account in two ways: the precise shape of the patient's histogram is employed in the calculation, and the complication response function is a function of the volume.

Causes and consequences of inhomogeneous dose distributions in radiation therapy

Reasons for delivering a non-uniform dose to the target volume are discussed. These include deliberate tailoring of dose to a non-uniform tumor burden or to a non-uniform expectation of the presence of disease, and undesired but unavoidable non-uniformities due to: technical factors; set-up uncertainty; and the need to avoid sensitive organs abutting the target volume. The consequences of non-uniform dose distributions are reviewed and it is suggested that: tumor control may be better characterized by the mean rather than the minimum target absorbed dose when the dose non-uniformity is not too great; modest dose deficits to small sub-volumes of the target volume may not be too deleterious; and modest dose increments to substantial sub-volumes of the target volume may be advantageous. Further modeling, and animal experiments in which tumors are non-uniformly irradiated are required to validate these hypotheses.

Strategies for treating possible tumor extension: some theoretical considerations

When there is a small possibility of cancer having extended to a region some distance from the main bulk of disease, it may be unclear whether to include that region in the target volume and, if so, what dose should be delivered to it. We have constructed a theoretical model that includes dose and volume relationships for both diseased and normal tissue. With this model one can calculate the change in tumor control probability (TCP) when varying doses are delivered to the regions of known and suspected disease. Values of TCP as a function of dose to the region of suspected disease have been calculated for a wide range of the variables on which the model depends. We conclude that the strategy of treating the region of suspected disease to about 70% of the dose delivered to the region of known disease is almost always better than not treating it at all, or treating both regions to a uniform but reduced dose designed to keep the probability of complication the same. The gain in TCP could be from 5 to 15% for situations of clinical interest.

An analysis of the contribution of computed tomography to the treatment outcome in bladder cancer

The survival pattern of 60 patients is reported and clinical details given. It has been possible to show significantly poorer survival in those patients whose tumour was incompletely enclosed by the 90% isodose, and the reasons for this have been discussed. The demonstration of pelvic lymph node enlargement has also been shown to be an indicator of poor prognosis.

Optimization of radiation therapy II: the critical-voxel model

The Complication Factor (CF) is an objective function recently introduced for use in the optimization of radiation therapy X treatment planning. Unlike earlier objective functions based upon physical/geometrical criteria, such as tumor dose uniformity, minimal integral-dose, etc., the CF stems from a simple biological/probabilistic model of radiation damage in living organisms. The CF defines the integral-response of an organ as that fraction of it rendered non-functional by irradiation; this parameter is significant if the net amount of damage to the organ is of importance but details of its spatial distribution are not as, for example, might be nearly the case with liver. This approach does not work, however, if complications in any one individual volume-element are critical, as with spinal cord or tumor recurrence. Several authors have addressed the latter problem, and we find that the probabilistic argument common to their methods fits comfortably within the CF framework. Drawing attention to the distinct differences between the integral-response and critical-voxel cases hopefully will be of value in the further development of biological modelling, for application in radiotherapy and elsewhere.

Dosimetric precision requirements in radiation therapy

Based on simple radiobiologic models the effect of the true distribution of absorbed dose in therapy beams on the response of uniform tumor volumes are investigated. Under assumption that the dose variation in the beam is small it is shown that the response of the tumor to radiation is determined by the mean dose to the tumor volume. Quantitative expressions are also given for the loss in tumor control probability as a function of the degree of dose variations around the mean dose level. When the dose variations are large the minimum tumor dose is best related to tumor control. It is finally shown that high tumor control rates can only be achieved with a very high accuracy in dose delivery. If the normalized dose response gradient is higher than 3, as is frequently the case, the relative standard deviation of mean dose in the target volume should be less than 3 per cent to achieve an absolute standard deviation in tumor control probability of less than 10 per cent.

Computed tomography and radiotherapy in the treatment of cancer

Computed tomography (CT) has shown to be of great value in the treatment of cancer with radiation therapy. It is used more and more in the estimation of tumor volume and for treatment planning, with the aid of the computerized treatment unit. At the James Graham Brown Cancer Center, Department of Radiation Oncology, CT has been used routinely for the treatment planning. From October 1, 1981 to June 30, 1982, we performed 180 CT scans for the treatment planning, 380 simple dose calculations, 237 complex treatment plans, and 42 intracavitary dosimetry using the treatment planning unit. This is a review of our experience with some illustrations. Accurate tumor dose can be delivered with reducing the complications with the use of CT and the computerized treatment unit.

User requirements on CT-based computed dose planning systems in radiation therapy. Presentation of 'check lists'

The expanding use of computers in radiation therapy procedures, especially the rapidly increasing use of digital CT-information, necessitates the coordination of the different systems in order to facilitate their developments. In order to define necessary demands for tomorrow a Nordic cooperation was initiated 1981 by NORDFORSK (Nordic co-operative organization for applied research), and a group of physicians and physicists having their daily work in this field of medicine and physics was invited to produce a report on 'User requirements on CT-based computed dose planning systems on radiation therapy'. The work has been done within the frame of NORDFORSK's activities and has been independent of the existing commissions and associations in the radiology field, but it has taken into consideration recommendations that have been given by or are being produced by other organizations. This report is a short summary of the complete paper which will be published in Acta Radiologica. The aim of this short version is to get an early presentation of the 'requirement lists' (see Appendix) which we think are of immediate importance.

Radiation treatment planning for bladder cancer: a comparison of cystogram localisation with computed tomography

A comparison has been made between the target volumes of radical radiotherapy treatment plans produced with the aid of marker cystograms, and target volumes derived from computed tomography (CT) scans in 60 patients with bladder cancer. This has demonstrated inadequacies of the cystograms due to the inability to delineate extravesical spread of tumour and, as many patients with bladder cancer had a significant residual urine, emptying the bladder by catheterisation may have given a false impression of the shape and size of the target volume. Analysis of the results showed that cystographic localisation resulted in serious underdosage of the tumour in 18% of patients and failure to include all the bladder in 37%. Conventionally produced target volumes showed potentially significant discrepancies in 85% of patients when compared with target volumes delineated by CT.

Optimization of radiation therapy: integral-response of a model biological system

Several radiotherapy treatment planning criteria have been proposed for dose distribution optimization. Here we present a simple mathematical model of an idealized biological system. From it we have derived an objective function designed to achieve an extremum for that particular plan which minimizes the probabilities of occurrence of unacceptable complications in healthy tissue and of recurrence or spread of disease. The model assumes that an organism is separable into physiologically discrete compartments or organs, each consisting of a set of microscopic functional units with their own dose-response characteristics. In analogy to the integral-dose, we define an integral-response parameter v as a measure of radiation-induced damage; the value of this v may be calculated for any given spatial distribution of dose in a compartment or organ. A Probability of Serious Complications function, PSC(v), then provides an estimate of the likelihood of occurrence of unacceptable complications. Special problems arising with paired organs (kidneys), "series" organs (spinal cord), and the recurrence and spread of disease are addressed. The PSC for the various organs and neoplasia can be combined to form a compound Complication Factor (CF) objective function; the lower the value of the CF, the better the overall plan. Prospects for making the model explicitly time/fractionation dependent, and for incorporating utility theoretic ideas, are discussed.

CT scan modification in the treatment of mediastinal Hodgkin's disease

Seventy-one patients with Hodgkin's disease who were initially treated at Johns Hopkins with radiation or radiation-chemotherapy from 1975--1980 had a five-year cumulative disease-free survival of I-A--100% (12 patients); II-A--85% (33 patients); II-B--83% (seven patients); III-A--75% (ten patients); and III-B--66% (nine patients). Fifty patients with mediastinal masses at the time of treatment demonstrated no marginal misses, two mediastinal recurrences (96% local control), and three lung disseminations. CT scan data yielded stage and treatment modification in 60% (9/15) of recent patients with mediastinal Hodgkin's disease. This demonstrates the need for routine thoracic scans and individual treatment planning in all mediastinal cases. Recommendations for combination treatment in early stage disease are made only for pericardial or extrathoracic chest wall extension based on CT scan findings, our low failure rates, radiation organ tolerances, and available relapse data in the literature, not arbitrary size designations from upright chest radiographs. It can be concluded that patients with mediastinal Hodgkin's disease require CT scan analysis to identify unusual patterns of presentations, sites at risk, and to allow for proper application of radiation portals and/or chemotherapeutic management.